Early diagnosis of HIV first infections: Combined screening assay (p24 antigen and HIV antibodies);Diagnostic precoce des primo-infections VIH: Utilisation d'un test de depistage combine (antigene p24 et anticorps anti-VIH)

Schweizerische Medizinische Wochenschrift

Volumn 129, Issue 8, 1999, Pages 319-322

  Yerly, S ^a   Simon, F ^b   Perrin, L ^a  

^a GENEVA UNIVERSITY HOSPITALS   (Switzerland)

^b BICHAT HOSPITAL   (France)

Author keywords

Diagnosis; p24 antigen; Primary HIV infection

Indexed keywords

HUMAN IMMUNODEFICIENCY VIRUS ANTIBODY; GAG PROTEIN;

ANTIBODY DETECTION; ARTICLE; EARLY DIAGNOSIS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MAJOR CLINICAL STUDY; VIRUS DETECTION; BLOOD; COMPARATIVE STUDY; IMMUNOLOGY; METHODOLOGY; SENSITIVITY AND SPECIFICITY; SERODIAGNOSIS; WESTERN BLOTTING;

AIDS SERODIAGNOSIS; BLOTTING, WESTERN; HIV ANTIBODIES; HIV CORE PROTEIN P24; HIV INFECTIONS; HIV SEROPOSITIVITY; HIV-1; HUMANS; SENSITIVITY AND SPECIFICITY;

EID: 0033608283     PISSN: 00367672     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (18)

1. Hampl H, Krapprell HP, Sawitzky D, Wilske W, Gurtler L. Detection of specific human immunodeficiency virus lgM antibodies. Med Microbiol Immunol Berl 1995;184:69-71.
2. De Saussure P, Yerly S, Tullen E, Perrin LH. HIV-1 nucleic acids detected before p24 antigenemia in a blood donor. Transfusion 1993;33:164-7.
3. Busch MP, Lee LL, Satten GA, Henrard DR, Farzadegan H, Nelson KE. Time course of detection of viral and serologic markers preceding human immunodeficiency virus type 1 seroconversion: implications for screening of blood and tissue donors. Transfusion 1995;35:91-7.
4. Schreiber GB, Busch MP, Kleinman SH, Korelitz JJ, for the Retrovirus Epidemiology Donor Study. The risk of transfusion-transmitted viral infections. N Engl J Med 1996;334: 1685-90.
5. Galetto-Lacour A, Kinloch-de Loës S, Hirschel B, Perrin L. Primo-infection VIH: un diagnostic souvent évoqué mais posé tardivement. Schweiz Med Wochenschr 1995;125: 341-6.
6. Ly TD, Lapeyre M, Brignoli E. Evaluation of VIDAS HIV DUO for the simultaneous detection of p24 Ag HIV-1 and HIV-2 antibodies. 12th World AIDS Conference, Geneva 1998 (abstract).
7. Carr JK, Salminen MO, Albert J, Sanders-Buell E, Gotte D, Birx DL. Full genome sequences of human immunodeficiency virus type 1 subtypes G and A/G intersubtype recombinants. Virology 1999;247:22-31.
8. Bobkov A, Kazennova E, Selimova L, Bobkova M, Khanina T, Ladnaya N. A sudden epidemic of HIV type 1 among injecting drug users in the former Soviet Union: identification of subtype A, subtype B, and novel gagA/envB recombinants. AIDS Res Hum Retroviruses 1998; 14:669-76.
9. Cark SJ, Saag MS, Decker WD, Campbell Hill S, Roberson JL, Veldkamp PJ, et al. High titers of cytopathic virus in plasma of patients with symptomatic primary HIV-1 infection. N Engl J Med 1991;324:954-60.
10. Baumberger C, Kinloch-de Loés S, Yerly S, Hirschel B, Perrin L. High level of circulating RNA in patients with symptomatic HIV-1 infection. AIDS 1993;7(Suppl 2):59-64.
11. Ho DD, Neumann AU, Perelson AS, Chen W, Lenoard JM, Markowitz M. Rapid turnover of plasma virions and CD4 lymphocytes in HIV-1 infection. Nature 1995;373: 123-6.
12. Wei X, Ghosh SK, Taylor ME, Johnson VA, Shaw GM, Emini EA, et al. Viral dynamics in human immunodeficiency virus type 1 infection. Nature 1995;373:117-22.
13. Pantaleo G, Graziosi C, Demarest JF, Butini L, Montroni M, Fox CH, et al. HIV infection is active and progressive in lymphoid tissue during the clinically latent stage of disease. Nature 1993;362:355-9.
14. Kinloch-de Loës S, Hirschel B, Hoen B, Cooper D, Tindall B, Carr A, et al. Zidovudine versus placeho in primary HIV infection: a randomized study. N Engl J Med 1995;333: 408-13.
15. Perrin L, Rakik A, Yerly S, Baumberger C, Kinloch-de Loës S, Pechère M, et al. Combined therapy with zidovudine and L-667, 661 in primary HIV infection. AIDS 1996; 10: 1233-7.
16. Perrin L, Yerly S, Charvier A, Figueras G, Schockmel G, Hirschel B. Zidovudine plus didanosine in primary HIV-1 infection. Antiviral Therapy 1997;2:9-15.
17. Lafeuillade A, Poggi C, Tamalet C, Profizi N, Tourres C, Costes O. Effects of a combination of zidovudine, didanosine, and lamivudine on primary human immunodeficiency virus type 1 infection. J Infect Dis 1997;175:1051-5.
18. Bulletin, Office fédéral de la santé publique (OFSP); No 40, 28. 9. 98, p. 18.